<DOC>
	<DOCNO>NCT01300234</DOCNO>
	<brief_summary>This multi-centre , double blind , double dummy , randomise , control study evaluate efficacy safety TDF 300mg QD versus ADV 10mg QD Chinese subject CHB . This study design demonstrate superiority TDF 300mg QD ADV 10mg QD treat Chinese subject CHB ( hepatitis B e antigen [ HBeAg ] positive subject HBeAg negative subject ) . It also provide long-term efficacy safety data ( 240 week ) TDF 300 mg administer daily .</brief_summary>
	<brief_title>Efficacy Safety Tenofovir Disoproxil Fumarate ( TDF ) 300mg Chinese Subjects With Chronic Hepatitis B ( CHB )</brief_title>
	<detailed_description>This multi-centre , double-blind , double-dummy , randomise , control study evaluate efficacy safety TDF 300mg QD versus ADV 10mg QD Chinese subject CHB . Four hundred ninety-four subject CHB ( 200 HBeAg positive subject 294 HBeAg negative subject ) randomise ( 1:1ratio ) either TDF 300mg QD ADV 10mg QD treatment arm . The primary endpoint proportion subject blood hepatitis B virus ( HBV ) deoxyribonucleic acid ( DNA ) &lt; 400copies/mL ( Roche COBAS Taqman HBV test ) Week 48 HBeAg positive subject CHB HBeAg negative subject CHB . This two-part study . The first treatment period ( baseline Week 48 ) investigate effect TDF ADV safety efficacy endpoint ; dose double-blind . This period follow 192 week subject receive open-label TDF ( Week 49 Week 240 ) . Subjects undergo regular safety efficacy assessment every 4 week first 12 week follow every 12 week total 5 year .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<mesh_term>Adefovir</mesh_term>
	<mesh_term>Adefovir dipivoxil</mesh_term>
	<criteria>HBeAg positive/negative CHB blood HBVDNA≥10^5 copies/mL elevate ALT Nucleoside nucleotide naïve CHB subject . Previous lamivudine treatment allow less 10 % total study population subject hepatocellular carcinoma ( HCC ) potential decompensated liver disease subject acute liver disease due cause subject medication history immunosuppressive therapy , immunomodulatory therapy , systemic cytotoxic agent , chronic antiviral agent include Chinese herbal medicine know activity HBV ( e.g. , lamivudine , hepatitis B immunoglobulin ( HBIg ) ) within previous 6 month prior randomisation study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>69 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>tenofovir disoproxil fumarate</keyword>
	<keyword>chronic hepatitis B</keyword>
	<keyword>adefovir dipivoxil</keyword>
</DOC>